-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Romidepsin is a histone deacetylase inhibitor that has been shown to be active as a single agent against relapsed or refractory peripheral T-cell lymphoma (PTCL)
.
Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) combination therapy is widely used as the first-line treatment of PTCL; however, the efficacy of this regimen is limited
Romidepsin is a histone deacetylase inhibitor lymphoma
This study is a randomized phase III study that compared the efficacy and safety of Ro-CHOP and CHOP regimens for previously untreated PTCL
.
All patients received 6 courses of CHOP (3 weeks/course); patients in the Ro-CHOP group received additional romidepsin (12 mg/m2, 3 weeks/course) on the 1st and 8th day of each course of treatment
Progression-free survival
Progression-free survivalFrom January 2013 to December 2017, a total of 421 patients (211 in the Ro-CHOP group and 210 in the CHOP group) were recruited
.
The median progression-free survival in the Ro-CHOP group and the CHOP group were 12.
The median progression-free survival of the Ro-CHOP group and the CHOP group were 12.
Overall survival
Overall survival30% or more of patients in the Ro-CHOP group reported grade 3/4 side effects requiring emergency treatment, including thrombocytopenia (Ro-CHOP group vs CHOP group: 50% vs 10%), neutropenia (49% vs 33%), anemia (47% vs 17%) and leukopenia (32% vs 20%)
In summary, on the basis of the CHOP regimen, the addition of romidepsin did not improve the progression-free survival, remission rate and overall survival of patients with previously untreated peripheral T-cell lymphoma, and it also increased ≥3 grades The incidence of adverse events requiring urgent treatment
On the basis of the CHOP regimen, the addition of romidepsin did not improve the progression-free survival, remission rate, and overall survival of patients with previously untreated peripheral T-cell lymphoma, and it also increased the need for emergency ≥ grade 3 The incidence of treatment-related adverse events was based on the CHOP regimen.
Original source:
Emmanuel Bachy, et al.
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA) in this message
